At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 241 enrolled
Drug / intervention
NT 201drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Randomized, Double-blind, Multicenter Study to Investigate the Safety and Duration of Effect of Different NT 201 Dose Groups Following the Treatment of Glabellar Frown Lines
In Brief
A Phase 2 clinical trial evaluating NT 201 for Moderate to Severe Glabellar Frown Lines. Completed, enrolled 241 participants across 9 sites in 2 countries.
Detailed Summary
The purpose of the study is to investigate the safety and duration of effect following different doses of Botulinum Toxin A (NT 201) in the treatment of glabellar frown lines (GFL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Glabellar Frown Lines
CountriesGermany, United States
CollaboratorsMerz Pharmaceuticals GmbH
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartJan 2019
Primary CompletionSep 2020
Study CompletionOct 2020
TodayJul 2026
First PostedJan 16, 2019
Enrollment StartJan 23, 2019
Primary CompletionSep 10, 2020
Study CompletionOct 8, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.5 years ago
Interventions
NT 201drug
Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% unpreserved Sodium Chloride (NaCl).